1.2 Million Local Made COVID-19 Vaccines Start Distribution To Regions In Indonesia

Illustration of the COVID 19 (ANTARA) vaccine

JAKARTA - The private pharmaceutical industry PT Biotis Pharmaceuticals Indonesia has distributed a total of 1.2 million doses of InaVac's COVID-19 vaccine ordered by the government to all regions in Indonesia.

"The Minister of Health (Menkes) has issued a Decree on the purchase of InaVac 5 million doses, 1.2 million more doses of which have been realized and distributed to all provinces," said PT Biotis Pharmaceutical Indonesia President Director FX Sudirman quoted by ANTARA, Tuesday 30 May.

A total of more than 3.7 million doses of vaccines ordered by the government, he said, were prepared to refill the needs of the people who were completed in the near future.

He said Biotis was conducting further clinical trials for teenagers who are now rolling at Soetomo Hospital, Surabaya.

"We have also started preparations for child vaccination to be carried out in the next quarter to obtain an Emergency Use Permit (EUA) for teenagers, especially school children who receive a booster dose of InaVac," he said.

FX Sudirman said Biotis and the researchers were trying to pay attention to the quality of vaccines, including efforts to maintain vaccine efficacy.

"This vaccine has been designed halally and this is a positive point, both primary and booster," he said.

Meanwhile, the mass vaccination activity which was carried out at the PT Biotis Building was attended by around 400 participants from the community around Mount Sindur.

The activity involved religious leaders, community leaders, and employees within the scope of PT Biotis Pharmaceuticals. Present at the activity were the Head of BPOM RI Penny K Lukito, Unair researcher Prof Fedix Abdul Rantam, and a number of relevant regional officials.